NCT07709195RecruitingPhase 2
Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant
Chlorophyllin as an Adjunct for Reducing Oral Mucositis in Myeloablative Total Body Irradiation
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
The goal of this phase II, single-arm interventional clinical trial is to evaluate whether oral sodium copper chlorophyllin (CHL) can reduce the frequency and severity of oral mucositis in patients aged 12-65 years undergoing myeloablative total body irradiation (TBI) as part of conditioning before their first allogeneic Hematopoietic Stem Cell Transplantation (HSCT). The main questions it aims to answer are: Does oral chlorophyllin reduce the incidence of Grade III and IV oral mucositis by day +28 after HSCT? Does oral chlorophyllin reduce the duration of severe oral mucositis and the need for total parenteral nutrition (TPN), opioid analgesics, and other treatment-related toxicities, while maintaining acceptable safety? Participants will: Receive oral sodium copper chlorophyllin 750 mg once daily (tablet or oral suspension) starting 48 hours before TBI conditioning and continuing until day +28 after HSCT. Undergo standard myeloablative TBI-based conditioning and allogeneic Hematopoietic Stem Cell Transplantation (HSCT) as part of routine clinical care. Have regular clinical assessments for oral mucositis, treatment-related toxicities, engraftment, and graft-versus-host disease (GVHD). Provide blood and saliva samples at predefined time points for cytokine and pharmacokinetic analyses.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (estimated)
- First submitted
- 11 Jul 2026
- Start date
- Oct 2024
- Primary completion date
- Mar 2027
- Lead sponsor
- Tata Memorial Centre
- Diseases
- Childhood cancers
- NCT number
- NCT07709195
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 17
- From Oct 2024 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Known hypersensitivity or contraindications to sodium chlorophyllin (CHL)
Who the study is looking for
- Patients ≥12 and ≤65 years of age
- First allogeneic stem cell transplant
- Total body irradiation dose (fractionated) ≥8 Gy
Age in the registry: 12 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Advanced Centre for Treatment Research and Education in Cancer Coordinator of this site? Confirm its status | Navi Mumbai | India | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.